GO
Loading...

Roche Holding AG

More

  • PARIS, Sept 18- French cancer immunotherapy specialist OSE Pharma has registered with market regulator AMF for an initial public offering aimed at financing late-stage trials of its Texopi drug for the most common form of lung cancer, the company said on Thursday.

  • For Roche CEO, celebrating failure is key to success Wednesday, 17 Sep 2014 | 8:06 AM ET

    LONDON, Sept 17- Roche Chief Executive Severin Schwan likes to crack open the champagne with his drug research teams at the end of a big project- especially when they fail.

  • LONDON, Sept 16- Roche's decision to buy U.S. biotech company InterMune for $8.3 billion last month was "exceptional" and not a sign of more ambitious plans for major acquisitions, the Swiss drugmaker's chief executive said on Tuesday.

  • Switzerland takes on its top drugmakers in price row Tuesday, 16 Sep 2014 | 5:46 AM ET

    *Roche, Novartis say low prices hurt R&D. ZURICH, Sept 16- Switzerland, home to the world's two biggest drugmakers, might be expected to give them an easy ride. But Roche and Novartis are finding no immunity in their home market from a European-wide price squeeze.

  • *Roche, Novartis say Lucentis is most appropriate drug. Avastin is not licensed for wAMD but it works in a similar way to authorized treatments for the condition- Lucentis, which is marketed by Novartis and Roche, and Eylea, from Bayer and Regeneron Pharmaceuticals.

  • Sept 12- Eli Lilly and Co's Cyramza stomach-cancer drug prolonged survival of patients with advanced colon cancer in a late-stage study, the U.S. drugmaker said on Friday. The 1,000- patient global study, called RAISE, involved patients who had previously failed to adequately benefit from Roche Holding AG's Avastin and other standard treatments.

  • *Departure a "loss" for Roche- analyst. ZURICH, Sept 4- Swiss drugmaker Roche said on Thursday that Art Levinson had resigned from its board of directors with immediate effect, in order to avoid any conflict of interest given his role as chief executive at Google's Calico.

  • Sept 3- U.S. drugmaker AbbVie Inc and Calico, a new company set up by Google Inc to cure diseases of aging, will each invest $250 million to help create Calico research facilities and collaborate on discovery and development of new medicines.

  • AbbVie, Calico forge deal against age-related diseases Wednesday, 3 Sep 2014 | 1:03 PM ET

    Sept 3- U.S. drugmaker AbbVie Inc and Calico, a new company set up by Google Inc to cure diseases of aging, will each invest $250 million to help create Calico research facilities and collaborate on discovery and development of new medicines.

  • Weaker healthcare stocks weigh on European equities Tuesday, 2 Sep 2014 | 12:40 PM ET

    *Bid target AstraZeneca falls; CEO says "back to normal". LONDON, Sept 2- A fall in major healthcare stocks, after drugmaker AstraZeneca tried to play down speculation about a new bid from Pfizer, pegged back European stock markets on Tuesday. "We wouldn't chase stocks at these levels," said HED Capital head Richard Edwards.

  • European equities dip as healthcare stocks weaken Tuesday, 2 Sep 2014 | 10:16 AM ET

    *Bid target AstraZeneca falls; CEO says "back to normal". LONDON, Sept 2- European shares slipped on Tuesday as major healthcare stocks fell after drugmaker AstraZeneca tried to play down speculation about a new bid from Pfizer. A 1.8 percent fall at AstraZeneca took the most points off the index.

  • *Novartis sees margins on LCZ696 better than for Diovan. BARCELONA, Sept 1- Sales forecasts for Novartis's new heart failure drug are being ramped up by analysts after strikingly good clinical trial results for a medicine doctors expect to transform treatment of the deadly disease.

  • *AstraZeneca shares up 2 percent. LONDON, Aug 29- Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.

  • Aug 27- Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its buck.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • NEW YORK, Aug 25- The S&P 500 was unable to hold the 2,000 mark after moving above the milestone level for the first time on Monday, but still managed to close at a record high, buoyed by financials and biotechnology stocks.

  • NEW YORK, Aug 25- The S&P 500 briefly hurdled above 2,000 for the first time on Monday, with financials and biotechnology stocks lifting the benchmark index to a record as investors make equities their asset of choice.

  • Europe closes higher on Draghi, Wall Street gains Monday, 25 Aug 2014 | 12:47 PM ET

    European shares closed higher on Monday following a key speech by Mario Draghi, the president of the European Central Bank.

  • There's still hunger for 'blockbuster' biotech deals Monday, 25 Aug 2014 | 10:58 AM ET
    Severin Schwan, chief executive officer Roche Holding.

    Roche's deal for InterMune is one of the few this year that returns to the traditional model of big pharma buying smaller biotech.

  • Biotechs rallied after Roche Holding AG agreed to buy InterMune Inc for $8.3 billion in cash, the latest vote of confidence in a sector that many, including Federal Reserve Chair Janet Yellen, are worried is overvalued. InterMune jumped 36 percent to $73.00, with the Nasdaq Biotech index up 2.4 percent.